ArticleResearch square2025
Patient-Reported Barriers to Healthcare Access Among Patients with Gastrointestinal Cancer: Insights from 45,000 Participants in the All of Us Research Program.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Gastrointestinal (GI) cancer patients often face care delays and cost-related unmet needs, increasing the probability for treatment nonadherence and adverse outcomes. The extent of these barriers within the first three months of diagnosis remains unclear. We aimed to identify early barriers to care for targeted interventions. Methods: A retrospective analysis using the Results: Among 45,061 GI cancer patients, 89.4% were underrepresented in biomedical research. Patients surveyed within three months of diagnosis had higher rates of delays in care (16.9% vs. 14.0%, p < 0.001), driven by affordability, childcare, and transportation (all p < 0.001). Overall cost-related unmet needs did not differ significantly (< 3 months 20.9% vs. >3 months 19.7%, p = 0.204), but differences in unmet prescription and alternative therapy needs persisted. After PSM, early-diagnosis patients had no differences in delays in care but were more likely to report cost-saving behaviors such as using lower-cost prescriptions (OR 1.28, 95% CI 1.05-1.54) and alternative therapies (OR 1.48, 95% CI 1.08-2.01) to save money. Conclusion: Cost-related unmet needs exist in the first three months after GI cancer diagnosis. This study underscores the importance of addressing social determinants of health early in cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.